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Decreased expression of messenger RNAs encoding endothelin receptors
and neutral endopeptidase 24.11 in endometrial cancer
F Pekonen', Nyman', Amma1a' and E-M Rutanen2
'Minerva Institutefor Medical Research, Tukholmankatu 2, SF-00250 HeL*inki; 2Department IIofObstetrics and Gynecology,
Helsinki University Central Hospital, SF-00290 Helsinki, Finland.
In this study, we used ever tranciptase-polymerase chain reaction (RT-PCR) to compare the
expression ofmRNAs enoding endotlhn-I (ET-i), endothelin reptors type A (ETA-R) and type B (ETR-R)
and ET-l1degrading enzyme neutral endopptidase 24.11 (NEP) in 15 endometrial cancer tissues and 13
normal endometrial issues. The reative kves of ET-1 mRNA in endomeial cancer tissues did not differ
from those in normal endometriumn Both ETA-R and ETr-R mRNA levels were sioanty lwer in
endometrial cancer tissue than in normal ndometrim (P<0.001). The complete lack of NEP mRNA in
endometrial cancer tisues was in marked contrast to results from normal endometrium (P<0.001). In
concusion, differential expesson ofmRNAs encodig ET-R and NEP in normal endomeium and endomet-
rial cancer suggests that ET action is altered in endotrial cancer compared with normal endometrium.
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Endothelin (ET) is a 21 amino acid peptide which was first
described in 1988 as a potent vasoconstrictor localised in
vascular endothelium (Yanagisawa et al., 1988). Subse-
quently, three ET isopepiades, called ET-1, ET-2 and ET-3,
with different biological activities, have been identified by
screening the huiman genomic DNA library (Inoue et al.,
1989). Although ET-1 was originally isolated from cultured
endothelial cells, it has become evident that the ETs are
widely distributed in different tissues and organs (Nunez et
al., 1990). The different potencies ofthe three isoforms ofthe
ET family opened up the possibility of the existence of
multiple ET receptor (ET-R) subtypes as well. Two distinct
ET receptors with different specificities have been cloned
(Arai et al., 1990; Sakurai et al., 1990). The type A
endothelin receptor (ETA-R) has high affinity for ET-1 and
ET-2 but little cross-reactivity with ET-3 and sarafotoxin
S6c, whereas type B receptor (ETB-R) is non-selective with
similar affinities for the different ETs and sarafotoxin S6c
(Sakurai et al., 1992). A third ET-R subtype with superhigh
affinity has been described but not yet cloned (Sokolovsky et
al., 1992). The ET-Rs are widely distributed in cell lines and
organs, but their relative abundance in different tisues
varies. ETB-R dominates in hippocampus, whereas ETA-R
dominates in the uterus (Williams et al., 1991). Neutral
endopeptidase 24.11 (NEP), also calW enkephalinase, is a
zinc-containing plasma membrane enzyme that efficiently
degrades a number of smal bioactive peptides, including the
ETs (Sokolovskly et al., 1990; Vijayaraghavan et al.,
1990).
In the human endometrium, ET-I has been shown to be
produced by both stromal and epithelial cells, with icreased
concentrations observed before and during menstruation
(Economos et al., 1992). The mRNAs for ET-1, ET-2 and
ET-3 have been detected in hunman endometrium throughout
the menstual cycle (O'Reilly et al., 1992). Also, pregnancy
endometrium (decidua) synthesises EU-i (Kubota et al.,
1992). The expression of ETA-R and ET,,rR mRNA in the
endometrium varies with the phase of the menstrual cycle,
the ratio of ETA-R to ETB-R being lowest in late secretory
phase (O'Reilly et al., 1992). NEP is present in the human
endometrium throughout the m strual cycle (Head et al.,
1993). The specific activity of the enzyme is correlated with
the plasma levels of progesterone and is highest in early and
mid-secretory phase (Casey et al., 1991).
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Little information on the role ofthe EU system in cancer is
available. Several cancer cell lines, including endometrial
cancer cel lines, have been shown to produce EU (Kusuhara
et al., 1990; Pekonen et al., 1992), but information on ET-R
mRNA expression in cancer tissue is scarce. In colon cancer,
decreased ET receptor activity has been reported (Inagaki et
al., 1992). Expression of NEP mRNA is typical for leukae-
mias, but has also been demonstrated in other malignancies
such as melanomas, gliomas and mesenchymal tumours (Car-
rel et al., 1983; Mechtersheimer and M61ler, 1989; Monod et
al., 1992). Information on EU-i mRNA expression in endo-
metrial cancer tissue is lacking. Neither EU-R nor NEP
mRNAs have been described in endometrial cancer tissue. In
this study we compared the mRNA expression of EU-related
substances in endometrial cancer and normal endometrium in
an attempt to elu:idate their potential role in the genesis of
endometrial cancer.
Mateial an m
Tismes
Endometrial cancer tissue was obtained from 15 women who
underwent hysterectomy for endometrial adenocarcinoma at
the Department of Obstetric and Gynecology, Helsinki
University Central Hospital. The mean age of the patients
was 62.6 years (range 47-80 years). Samples of normal
endometrium were obtained from 13 women who underwent
laparoscopic tubal ligation at the Hyvink district Hospital,
Finland. The mean age ofthese women was 42.2 years (range
35-47). The samples were collected with the approval of the
Local Ethical Committees. The tissue samples were snap
frozen in liquid nitrogen im iatey after removal and
stored at -80 C until processed. Routine haematoxylin and
eosin-stained paraffin sections were pre for histological
evalaton. The dating of the endometrial samples was based
on the first day of the last menstrual period and histological
examination according to the method of Noyes et al.
(1950).
RNA isolation
All reagents used for RNA isolation were molcular biology
reagents from Sigma (St Louis, MO, USA). The guanidium
thiocyanate methd (Chomczynsli and Sacchi, 1987) was
used to isolate total RNA.ETrecpkx and NE in __domd cacer
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Reverse transcriptase-polvmerase chain reaction (RT-PCR)
A random-primed cDNA library was prepared from 1 iLg of
RNA with the Moloney murine leukaemia virus reverse
transcriptase according to the manufacturer's recommenda-
tions (Gibco-BRL, NY, USA). The reaction was stopped by
incubating at 95°C for 5 min and was then quick chilled on
ice. The cDNA was amplified according to Takeda et al.
(1992) using amplification primers based on previously
reported sequences (Table I). The concentration of primers
was 0.5 JAM, of magnesium chloride, 1.5 mM and of Taq
polymerase 1.25 U (Promega) in 50fLI buffer (Promega). In
brief, 3 tLI of cDNA reaction mixture was used for
amplification in the presence of 1 mM each of dATP, dGTP
and dTTP, 0.8 mM dCTP and 0.1 I l of [32PJdCTP (3000 mCi
mmol -, Amersham, Bucks, UK). Thirty cycle products, which
were within the linear logarithmic phase of the amplification
curve, were analysed (Figure 1). Actin (23 cycles, chosen to
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Fgre 1 Amplification of ET-1 (0), NEP (0), ET,-R (U),
ETB-R (0) and actin (A) mRNA from human endometrium
using RT-PCR. Quantification of RT-PCR product was based
on incorporation of [3-'P]dCTP into the specific amplification
products at 24-36 cycles. The amplification products were
separated by agarose gel electrophoresis and visualised by
ethidium bromide, and radioactivities in specific bands were
counted.
be within the logarithmic linear phase of actin amplification)
was used as an internal control, and the reaction was per-
formed in the same tube as the specific ET, ET-R and NEP
reactions. The radioactivity in the specific PCR bands in
low-melting Nu Sieve GTG agarose (FMC Bio Products,
Rockland, ME, USA) gel was counted. Results were ex-
pressed as relative levels of specific mRNAs normalised to
actin. In all experiments, two control reactions, one contain-
ing no mRNA and another containing mRNA but without
reverse transcriptase, were included. The radioactivity in the
control sample without mRNA was in each instance sub-
tracted from the radioactivity in specific PCR bands.
Southern blot hvbridisation
The digoxigenin-1l-dUTP (DIG)-based labelling and detec-
tion system from Boehringer Mannheim. with 3'-tailing of
oligonucleotides, was used for Southern hybridisation. The
PCR products were blotted by capillary transfer onto nylon
membrane (Zeta-Probe, Bio-Rad). The blotted membrane
was probed according to the manufacturer's instructions in
5 ml of hybridisation mixture containing 5 x SSC, 0.1% N-
laurosylsarcosine, 1% blocking reagent. 0.02% sodium
dodecyl sulphate (SDS). and DIG-labelled oligonucleotides
which occurred between the two primers used in the specific
PCR reactions (Table I).
Statistics
Student's t-test for non-paired samples was used when
mRNA expression in cancer tissues and normal tissues was
compared.
Results
The 30 cycle PCR products were within the linear logarith-
mic phase of the amplification curve for ET-l, NEP. ETA-R
and ETB-R (Figure 1). The sizes of the RT-PCR products
were as predicted from the genomic maps (Table I and
Figure 2). By Southern hybridisation single bands corre-
sponding to the RT-PCR bands in agarose gels were seen in
each case (results not shown). The ET-1 mRNA levels in
human endometrial cancer tissues and samples of normal
endometrium did not differ (P = 0.959) (Figure 3). In con-
trast, both ETA-R and ETB-R mRNA levels were significantly
lower (P<0.001) in endometrial cancer tissues than in nor-
mal endometrial tissues (Figure 4), and NEP mRNA could
not be detected in any of endometrial cancer tissues (Figure
3). This was in striking contrast to the results from normal
endometrial tissues, in which NEP mRNA was detectable in
each tissue studied (Figure 3, P<0.001).
Table I Primers used in PCR amplifications
Nucleotide Product
Gene Oligonucleotide sequence nunber size (bp) Reference
ET-I 5'primer: TGCTCCTGCTCGTCCCTGATGGATAAAGAG 157-186 462 Itoh et al., 1988
3' primer GGTCACATAACGCTCTCTGGAGGGCTT 592-618
internal oligonucleotide: CCAAATGATGTCCAGGTGGCAGAAGTAGTA 193-219
ETA-R 5' primer: CACTGGTTGGATGTGTAATC 38-57 367 Adachi et al., 1991
3' primer: GGAGATCAATGACCACATAG 386-405
internal oligonucleotide: GCAAGACTGGCTATCAGCGCGTTG 345-368
ETB-R 5' primer: TCAACACGGTTGTGTCCTGC 308-368 529 Sakamoto et al.,
3' primer: ACTGAATAGCCACCAATCT-T 818-837 1991
internal oligonucleotide: GGATGAAGCAAGCAGATTCGCAG 754-776
NEP 5' pnmer: GGTCATAGGACACGAAATCAC 1736-1757 520 Malfroy et al.. 1988
3' pnmer: TGAAGATCACCAAACCCGGCACTT 2232-2256
internal oligonucleotide: CACCAGTCAACGAGGTCTCCATC 1794- 1816
b-actin 5' primer: CCCAGGCACCAGGGCGTGAT 154-173 260 Ponte et al.. 1984
3' primer: TCAAACATGATCTGGGTCAT 396-415
internal oligonucleotide: TACAATGAGCTGCGTGTGGCTCCCGAG 312-338 *~~~~~~~--
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Figure 2 Amplification products of actin, ET-1, ETA-R, ETB-R
and NEP mRNAs in three representative endometrial samples.
The mRNA was reverse transcribed and amplified by PCR (30
cycles). The RT-PCR products were separated by agarose gel
electrophoresis and visualised by ethidium bromide. The base
pair markers are indicated on the left. Lane 0; control samples
without mRNA; lanes 1-3; three different endometria (cycle days
8. 19. 27). The predicted sizes for the amplification products
were: ET. 462 bp; ETA-R. 367 bp: ETB-R. 529 bp; NEP, 520 bp:
actin 260 bp.
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Figure 3 The relative levels (mean + s.d.) of mRNAs for (a)
ET-1 and (b) NEP in endometrial cancer tissues (ca. solid col-
umn) and mean of triplicate measurements of normal endometrial
tissue specimen. The day of the cycle is indicated below each
column. Quantification of RT-PCR product (30 cycles) was
based on incorporation of [3-'PJdCTP in the specific amplification
product. Actin mRNA was amplified in the same RT-PCR
reaction (23 cycles). The amplification products were separated
by agarose gel electrophoresis, visualised by ethidium bromide
and radioactivities in the specific bands were counted. Data are
expressed as relative level of specific mRNA (= c.p.m. of specific
bands divided by c.p.m. of actin bands). Radioactivity in control
samples without mRNA was subtracted from all values.
D6cusos
The diverse distribution of ET isoforms and subtypes of ET
receptors suggest that ET has multiple functions in different
tissues. This study shows that in human endometrial cancer
ET-I mRNA is expressed, whereas the relative levels of
mRNAs encoding ETRs or NEP are low or undetectable.
Although ET production has been demonstrated in many
human cancer cell lines (Kusuhara et al.. 1990), little inform-
ation on the ETsystem in human cancer tissue is available. It
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Figre 4 The mean (+s.d.) relative levels of mRNA for (a)
ETA-R and (b) ETB-R in 15 endometrial cancer tissues (solid
column) and in 13 normal endometrial tissues (the day of the
cycle is indicated below each column). Quantification of
RT-PCR product was performed as described in legend to
Figure 3. The samples are the same as in Figure 3.
has been shown that some pulmonary tumours express ET-1
mRNA (Giaid et al.. 1990). and that the epithelial cancer
cells in human colon cancer tissue bind ET-1 minimally
(Inagaki et al.. 1992). Our results on low or lacking ET-R
mRNA expression in endometrial cancer are thus in good
agreement with those of Inagaki et al. (1992). The data are
also in keeping with a recent observation that ET binding in
endometrial cancer tissue is lower than that in normal endo-
metrium from premenopausal women (Ben-Baruch et al.,
1993). Endometrial adenocarcinoma tissue typically consists
ofepithelial cells with few stromal elements. The absence of a
stromal compartment might explain decreased ET-R expres-
sion in endometrial cancer if stromal cells were the major site
of ET-R expression in the endometrium as described in
breast tissue (Baley et al., 1990). On the other hand, it has
been shown that in normal endometrium the glandular
epithelium and blood vessels have a high density of ET
binding sites (Davenport et al., 1991). If this is the case. it
suggests that endometrial adenocarcinoma cells differ from
normal endometrial epithelial cells regarding ET binding.
Contaminating endothelial cells (Davenport et al.. 1991)
might account for the low levels of ET-R mRNA in endo-
metrial cancer tissues. Further studies are, however, needed
to clanrfy the cellular localisation of ET binding in endo-
metnal cancer. No information on ET-R expression in post-
menopausal endometrium is available, but ET-1 binding to
myometnal membranes is lower in tissue samples obtained
from post-menopausal women than from premenopausal
pregnant women (Schiff et al., 1993).
The relative levels of ET-1 mRNA in different endometrial
cancer cell lines are reflected in their ET-1 secretion, as
shown previously (Pekonen et al., 1992). The expression of
ET-1 mRNA in endometrial cancer tissues is in agreement
with an epithelial cell origin of ET-1. The finding that the
relative levels of ET-1 mRNA in endometrial cancer tissue
did not differ from those in normal endometrium during
different phases of the menstrual cycle suggests that the ET-1
expression in endometrial epithelium remains unchanged des-
pite malignant transformation.
Immunoreactive NEP has been localised exclusively to the
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stromal cells in the human endometnrum with maximal
activity in mid-secretory phase (Casey et al., 1991; Head et
al., 1993). In agreement with this, the highest levels of NEP
mRNA were detected in early secretory phase endometrium
in this study. Stromal cell origin may account for the absence
of NEP mRNA in endometrial cancer tissues. Another
explanation may be the age of endometrial cancer patients.
In this study, they were all post-menopausal. It is obvious
that post-menopausal endometrium differs from premeno-
pausal endometrium regarding autocrine and paracrine fac-
tors regulated by ovarian steroid hormones. It appears that
the NEP mRNA expression in the endometrium is not regu-
lated by oestrogens, since NEP mRNA levels in post-meno-
pausal endometrium have been reported to be similar to
those in proliferative phase endometrium (Head et al., 1993).
Even progesterone's role in the regulation of NEP remains
unclear. Immunoreactive NEP was weak in proliferative
endometrium, strong in mid-secretory endometrium and
almost non-existent in predecidualised/decidualised endo-
metrium in spite of high serum progesterone levels (Head et
al., 1993). Thus, NEP expression in the endometrium appears
to be more differentiation than hormone dependent.
The low expression of ET-R in endometrial cancer implies
decreased ET action and, consequently, decreased vasocon-
striction in cancer tissue compared with normal endo-
metrium. Whether or not the lack of NEP has a role in
endometrial carcinoma is more difficult to speculate, since
NEP hydrolyses ET-1 as well as a number of other bioactive
peptides, which may have effects on tumour growth.
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